Regeneron pharmaceuticals (regn) faces securities class action after losing $9 billion value following q3 2024 earnings report – hagens berman

Regn investors with losses encouraged to contact the firm before mar. 10th, 2025 deadline regn investors with losses encouraged to contact the firm before mar. 10th, 2025 deadline

REGN Ratings Summary

REGN Quant Ranking